Dosage Information for Actemra: Forms, Potencies, Usage, and Additional Details
Actemra, a medication used to treat various autoimmune and inflammatory conditions, belongs to a group of drugs called interleukin-6 receptor antagonists. This article provides an overview of Actemra's uses, dosages, and administration methods.
Actemra is primarily used to treat conditions such as rheumatoid arthritis, systemic juvenile idiopathic arthritis (SJIA), polyarticular juvenile idiopathic arthritis, and systemic sclerosis related to interstitial lung disease. For SJIA, Actemra may be given as an intravenous (IV) infusion or a subcutaneous injection, with the dosage determined by the doctor based on the patient's condition and response to the drug.
In the case of body weight less than 30 kg (approximately 66 lb), the IV infusion dosage is 12 mg per kg, and the subcutaneous injection dosage is 162 mg every 2 weeks. For body weight 30 kg or more, the IV infusion dosage is 8 mg per kg, and the subcutaneous injection dosage is 162 mg every week.
For cytokine release syndrome (CRS), Actemra is given as an IV infusion, with the dosage based on body weight and potentially repeated up to four times if needed. Actemra is also authorised for the treatment of severe or life-threatening CRS associated with COVID-19 in children 2 years of age and older, with the dosing generally aligning with weight-based intravenous dosing similar to adults.
Actemra is typically a long-term treatment for all its approved uses except CRS. In the context of COVID-19, the current recommended dosage for adults is an IV single dose of 8 mg/kg (up to a maximum of 800 mg) given once. For children, the dosing is weight-based, with approximately 12 mg/kg for those under 30 kg and 8 mg/kg for those 30 kg or more, administered once.
It's important to note that Actemra contains the active drug tocilizumab, which is a biologic medication. Actemra comes in different strengths: 20 mg per mL for IV infusion, and 162 mg per 0.9 mL for subcutaneous injection. Actemra isn't currently available in a tablet form, but comes as a solution for IV infusion or subcutaneous injection.
For patients with renal problems, the dosage of Actemra will be prescribed by the doctor based on the patient's specific condition, as there are no dosage adjustments provided by the manufacturer for this condition.
Actemra is a brand-name prescription medication used to treat giant cell arteritis, rheumatoid arthritis, systemic sclerosis related to interstitial lung disease, cytokine release syndrome, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis. For giant cell arteritis, Actemra is given as a subcutaneous injection, usually at 162 mg every 1 to 2 weeks.
In the case of COVID-19, Actemra has received an emergency use authorization (EUA) for treatment in certain cases. However, no evidence indicates approved subcutaneous use of Actemra for COVID-19 treatment. The dosing regimen reflects current clinical guidelines and emergency use settings in 2025 as per authoritative prescribing information.
Deciders should carefully consider Actemra, a drug employed in the treatment of multiple medical-conditions such as rheumatoid arthritis, as it belongs to the group of interleukin-6 receptor antagonists. When treating systemic juvenile idiopathic arthritis (SJIA), the drug can be administered via intravenous infusion or subcutaneous injection, with the dosage depending on the patient's body weight and health-and-wellness status. The science behind Actemra's therapies-and-treatments has been instrumental in managing various autoimmune and inflammatory diseases, positively impacting health-and-wellness for millions.
